Table 3.
Secondary outcomes by treatment allocation
| Outcomes | Bath additives | No bath additives | Difference (95% CI) | |
|---|---|---|---|---|
| Univariate | Adjusted | |||
| Mean (SD) repeated monthly measures over 52 weeks | 7.3 (6.3) | 8.4 (6.4) | 0.99 (0.03 to 1.96) | 0.75 (−0.05 to 1.55) |
| Median (interquartile range) disease specific quality of life: | ||||
| Baseline | 2 (1-6) | 3 (1-7) | ||
| 16 weeks | 2 (0-5) | 3 (1-7) | 1.00 (0.09 to 1.91) | 0.29 (−0.57 to 1.14) |
| 52 weeks | 2 (0-5) | 2 (0-6) | 0.00 (−0.93 to 0.93) | −0.29 (−1.36 to 0.79) |
| Mean (SD) generic quality of life*: | ||||
| Baseline | 0.90 (0.1) | 0.90 (0.1) | 0.00 (−0.02 to 0.02) | |
| 16 weeks | 0.91 (0.1) | 0.89 (0.1) | 0.01 (−0.01 to 0.03) | |
| 52 weeks | 0.90 (0.1) | 0.91 (0.1) | −0.01 (−0.03 to 0.01) | |
| Total No of TCS/TCI prescriptions | 325 | 346 | ||
| Median (interquartile range) No of TCS/TCI prescriptions | 0 (0-2) | 1 (0-3) | ||
| Median (interquartile range) No of exacerbations | 1 (0-2) | 1 (0-3) | 1.33 (1.02 to 1.75)† | 1.24 (0.96 to 1.60)† |
TCS=topical corticosteroid; TCI=topical calcineurin inhibitor.
*
Child health utility-9D.
†
Relative risk (95% CI).